ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 95 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,810,896 | -20.9% | 1,186,837 | +11.2% | 0.00% | -25.0% |
Q2 2023 | $30,117,033 | +95.4% | 1,067,601 | +19.2% | 0.00% | +100.0% |
Q1 2023 | $15,409,916 | +89160.4% | 895,925 | +4.5% | 0.00% | 0.0% |
Q4 2022 | $17,264 | -99.9% | 857,217 | +2.5% | 0.00% | -33.3% |
Q3 2022 | $18,112,000 | -17.5% | 836,210 | +7.0% | 0.00% | 0.0% |
Q2 2022 | $21,958,000 | -28.6% | 781,444 | +17.3% | 0.00% | -25.0% |
Q1 2022 | $30,732,000 | -44.7% | 666,064 | +0.7% | 0.00% | -42.9% |
Q4 2021 | $55,581,000 | +29.8% | 661,211 | +2.9% | 0.01% | +16.7% |
Q3 2021 | $42,826,000 | +81.4% | 642,654 | +44.8% | 0.01% | +100.0% |
Q2 2021 | $23,608,000 | +48.3% | 443,765 | +21.0% | 0.00% | +50.0% |
Q1 2021 | $15,917,000 | -7.6% | 366,840 | +10.6% | 0.00% | -33.3% |
Q4 2020 | $17,233,000 | +190.6% | 331,789 | +82.9% | 0.00% | +200.0% |
Q3 2020 | $5,931,000 | -23.9% | 181,447 | +11.8% | 0.00% | -50.0% |
Q2 2020 | $7,795,000 | – | 162,335 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |